Picard Medical is trading at $5.43, up 5.9% (+5.85%), after Q2 revenue nearly doubled expectations, reaching approximately $2.95 million versus consensus near $1.55 million.
- Revenue grew 39%, driven by stronger U.S. sales; gross profit was approximately $0.6 million.
- Q2 net loss remained substantial at roughly $5.7 million, leaving financing and cash-burn concerns.
- Follow-through buying extends the August 24, 2026 earnings-driven surge, while broader markets were only modestly higher, suggesting a primarily company-specific catalyst.